GabowP.A., DuleyI., JohnsonA.M.Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. Am J Kidney Dis1992; 20: 140–143.
4.
NauliS., AlenghartF.J., LuoY.Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Gen2003; 33: 129–137.
5.
GranthamJ.J.Fluid secretion, cellular proliferation and the pathogenesis of renal epithelial cysts. J Am Soc Nephrol1993; 3: 1841–1857.
6.
TorresV.E., HarrisP.C.Autosomal dominant polycystic kidney disease: the last 3 years. Kidney International2009; 76: 149–168.
7.
RavineD., GibsonR.N., WalkerR.G., SheffieldL.J., Kincaid-SmithP., DanksD.M.Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet1994; 343: 824–827.
8.
PeiY., ObajiJ., DupuisA., PatersonA.D., MagistroniR., DicksE., ParfreyP., CramerB., CotoE., TorraR., San MillanJ.L., GibsonR., BreuningM., PetersD., RavineD.Unified Criteria for Ultrasonographic Diagnosis of ADPKD. J Am Soc Nephrol2009; 20: 205–212.
9.
GabowP.A., JohnsonA.M., KaehnyW.D., KimberlingW.J., LezotteD.C., DuleyI.Y., JonesR.H.Factors affecting the progression of renal disease in autosomal dominant polycystic kidney disease. Kidney Int1992; 41: 1311–1319.
10.
HarrisP.C., BaeK.T., RossettiS., TorresV.E., GranthamJ.J., ArleneB., ChapmanA.B., Guay-WoodfordL.M., KingB.F., WetzelL.H., BaumgartenD.A., KenneyP.J., ConsugarM., KlahrS., BennettW.M., MeyersC.M., ZhangQ., ThompsonP.A., ZhuF., Miller JP and the CRISP: Cyst Number but Not the Rate of Cystic Growth Is Associated with the Mutated Gene in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol2006; 17: 3013–3019.
11.
BearJ.C., ParfreyP.S., MorganJ.M., MartinC.J., CramerB.C.Autosomal dominant polycystic kidney disease: New in-formation for genetic counselling. Am J Med Genet1992; 43: 548–553.
12.
PeiY.A “two-hit” model of cystogenesis in autosomal dominant polycystic kidney disease?Trends Mol Med2001 Apr; 7(4): 151–6.
13.
ChapmanA.B., JohnsonA.M., GabowP.A., SchnienRW:Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol1994; 5: 1349–1354.
14.
CadnapaphornchaiM.A., McFannK., StrainJ.D., MasoumiA., SchrierR.W.Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int2008; 74: 1192–1196.
15.
ChapmanA.B., Guay-WoodfordL.M., GranthamJ.J., TorresV.R., BaeK.T., BaumgartenD.A., KenneyP.J., KingB.F.Jr., GlocknerJ.F., WetzelL.H., BrummerM.E., O'NeillW.C., RobbinM.I., BennettW.M., KlahrS., HirschmanG.H., KimmelP.I., ThompsonP.A., and MillerJ.P.Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int2003; 64: 1035–1045.
16.
LeeY.R., LeeK.B.Reliability of Magnetic Resonance Imaging for Measuring the Volumetric Indices in Autosomal-Dominant Polycystic Kidney Disease: Correlation with Hypertension and Renal Function. Nephron Clin Pract2006; 103: c173–c180.
17.
BaeK.T., ZhuF., ChapmanA.B., TorresV.E., GranthamJ.J., Guay-WoodfordL.M., BaumgartenD.A., KingB.F.Jr., WetzelL.H., KenneyP.J., BrummerM.E., BennettW.M., KlahrS., MeyersC.M., ZhangX., ThompsonP.A., MillerJ.P.and the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Magnetic Resonance Imaging Evaluation of Hepatic Cysts in Early Autosomal-Dominant Polycystic Kidney Disease: Polycystic Kidney Disease Cohort. Clin J Am Soc Nephrol2006; 1: 64–69.
GranthamJ.J., ChapmanA.B., TorresV.E.Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes:Clin J Am Soc Nephrol2006; 1: 148–157.
20.
MagistroniR., HeN., WangK., AndrewR., JohnsonA., GabowP., DicksE., ParfreyP., TorraR., San-MillanJ.L., CotoE., Van DijkM., BreuningM., PetersD., BogdanovaN., LigabueG., AlbertazziA., HateboerN., DemetriouK., PieridesA., DeltasC., St George-HyslopP., RavineD., PeiY.Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol2003; 14: 1164–1174.
21.
ChoukrounG., ItakuraY, AlbouzeG., ChristopheJ.L., ManN.K., GrunfeldJ.P., JungersP.Factors Influencing Progression of Renal Failure in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol1995; 6: 1634–1642.
22.
DalgaardO.Z.Bilateral polycystic disease of the kidneys. Acta Med Scand1957; 328: 1–255.
23.
KingB.F., ReedJ.E., BergstralhE.J., SheedyPF2nd, TorresV.E.Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease:J Am Soc Nephrol2000; 11: 1505–1511.
24.
PerroneR.Imaging Progression in Polycystic Kidney Disease. N Engl J Med2006; 354: 2181–2183.
25.
BaeK.T., and GranthamJ.J.Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol2010; 6: 96–106.
26.
KistlerA.D., PosterD., KrauerF., WeishauptD., RainaS., SennO., BinetI., SpanausK., WuthrichR.P., and SerraA.L.: Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int2009; 75: 235–241.
27.
GranthamJ.J., VicenteE., TorresV.E., ChapmanA.B., Guay-WoodfordL.M., BaeK.T., KingB.F., WetzelL.H., BaumgartenD.A., KenneyP.J., HarrisP.C., KlahrS., BennettW.M., HirschmanG.N., MeyersC.M., ZhangX., ZhuF., Miller JP for the CRISP Investigators. Volume progression in polycystic kidney disease. N Engl J Med2006; 354: 2122–2130.
28.
SiseC., KusakaM., WetzelL.H., WinklhoferF., CowleyB.D., CookL.T., GordonM., GranthamJ.J.Volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography. Kidney Int2000; 58: 2492–2501.
29.
AntigaL., PiccinelliM., FasoliniG., Ene-IordacheB., OndeiP., BrunoS., RemuzziG., RemuzziA.Computed Tomography Evaluation of Autosomal Dominant Polycystic Kidney Disease Progression: A Progress Report. Clin J Am Soc Nephrol2006; 1: 754–760.
30.
BaeK.T., CommeanP.K., LeeJ.Volumetric measurement of renal cysts and parenchyma using MRI: phantoms and patients with polycystic kidney disease. J Comput Assist Tomogr2000; 24: 614–619.
31.
NatalinR.A., PrinceM.R., GrossmanM.E., SilversD., LandmanJ.Contemporary applications and limitations of magnetic resonance imaging contrast materials. J Urol2010; 183(1): 27–33.
32.
BaeK.T., TaoC., ZhuF., BostJ.E., ChapmanA.B., GranthamJ.J., TorresV.E., Guay-WoodfordL.M., MeyersC.M., Bennett WM and Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). MRI-based Kidney Volume Measurements in ADPKD: Reliability and Effect of Gadolinium Enhancement. Clin J Am Soc Nephrol2009; 4: 719–725.
33.
GranthamJ.J., CookL.T., TorresV.E., BostJ.E., ChapmanA.B., HarrisP.C., Guay-WoodfordL.M., BaeK.T., for the CRISP Investigators. Determinants of renal volume in autosomal dominant polycystic kidney disease. Kidney Int2008; 73: 108–116.
34.
MignaniR., CorsiC., De MarcoM., CaianiE.G., SantucciG., CavagnaE., SeveriS., CagnoliL.Assessment of Kidney Volume in Polycystic Kidney Disease Using Magnetic Resonance Imaging without Contrast Medium. Am J Nephrol2011; 33: 176–184.
35.
RuggenentiP., RemuzziA., OndeiP., FasoliniG., AntigaL., Ene-IordacheB., RemuzziG., EpsteinF.H.Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int2005 Jul; 68(1): 206–16.
36.
PericoN., AntigaL., CaroliA., RuggenentiP., FasoliniG., CafaroM., OndeiP., RubisN., DiadeiO., GherardiG., PrandiniS., PanozoA., BravoR.F., CarminatiS., De LeonF.R., GaspariF., CortinovisM., MotterliniN., Ene-IordacheB., RemuzziA., RemuzziG.Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol2010 Jun; 21(6): 1031–40.
37.
SerraA.L., PosterD., KistlerA.D., KrauerF., RainaS., YoungJ., RentschK.M., SpanausK.S., SennO., KristantoP., ScheffelH., WeishauptD., and WüthrichR.P.Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease. New Eng J Med2010; 363(9): 820–829.
38.
WalzG., BuddeK., MannaaN., NürnbergerJ., WannerC., SommererC., KunzendorfU., BanasB., HörlW.H., Ober-müllerN., ArnsW., PavenstädtH., GaedekeJ., BüchertM., MayC., GschaidmeierH., KramerS., EckardtK.Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease. New Eng J Med2010; 363(9): 830–840.
39.
WatnickT., and GerminoG.G.mTOR Inhibitors in Polycystic Kidney Disease. New Eng J Med2010; 363(9): 879–881.
40.
GranthamJ.J., BennettW.M., PerroneR.D.mTOR inhibitors and autosomal dominant polycystic kidney disease. N Engl J Med.2011; 364(3): 286–7.
41.
IrazabalM.V., TorresV.E., HoganM.C., GlocknerJ., KingB.F., OfstieT.G., KrasaH.B., OuyangJ., CzerwiecF.S.Short-term effects of tolvaptan on renal function and volume in patients with Autosomal Dominant Polycystic Kidney Disease. Kidney Int2011, on-line 4 maggio 2011.
